Abstract
AIMS: Our study aimed to assess whether a single pill concept (SPC) is superior to a multi-pill concept (MPC) in reducing cardiovascular (CV) events, all-cause death, and costs in CV patients.
METHOD AND RESULTS: Anonymized medical claims data covering 2012-2018, including patients with hypertension, dyslipidaemia, and CV diseases who started a drug therapy either as SPC or identical MPC were analysed after 1:1-propensity score matching. Hospitalizations with predefined CV events, all-cause mortality, and costs were studied in 25 311 patients with SPC and 25 311 patients with MPC using incidence rate ratios (IRRs) and non-parametric tests for continuous variables.IRRs were significantly lower for SPC: stroke (IRR = 0.77; 95% CI 0.67-0.88; P < 0.001), transitory ischaemic attack (IRR = 0.61; 95% CI 0.48-0.78; P < 0.001), myocardial infarction (IRR = 0.76; 95% CI 0.63-0.90; P = 0.0016), coronary artery disease (IRR = 0.66; 95% CI 0.57-0.77; P < 0.001), heart failure (IRR = 0.59; 95% CI 0.54-0.64; P < 0.001), acute renal failure (IRR = 0.54; 95% CI 0.56-0.64; P < 0.001), all cause hospitalization (IRR = 0.72; 95% CI 0.71-0.74; P < 0.001), CV hospitalization (IRR = 0.63; 95% CI 0.57-0.69; P < 0.001), and all-cause mortality (IRR = 0.62; 95% CI 0.57-0.68; P < 0.001). Mean time to first events and time to death were also in favour of SPC. Mean total costs were 4708€ for SPC vs. 5.669€ for MPC, respectively (mean ratio 0.830, P < 0.001).
CONCLUSION: SPC is associated with lower incidence rates of CV events, time to CV events, and all-cause death, and is superior regarding pharmacoeconomic parameters and should therefore become standard of care to improve outcomes and reduce healthcare costs.
| Original language | English |
|---|---|
| Journal | European heart journal. Cardiovascular pharmacotherapy |
| Volume | 10 |
| Issue number | 8 |
| Pages (from-to) | 686-693 |
| Number of pages | 8 |
| DOIs | |
| Publication status | Published - 11.01.2025 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Research areas and keywords
- Humans
- Female
- Cardiovascular Diseases/economics
- Male
- Aged
- Middle Aged
- Drug Costs
- Time Factors
- Treatment Outcome
- Cardiovascular Agents/economics
- Retrospective Studies
- Cost-Benefit Analysis
- Cost Savings
- Economics, Pharmaceutical
- Databases, Factual
- Cause of Death
- Incidence
- Hospitalization
Fingerprint
Dive into the research topics of 'Effect of a single pill concept on clinical and pharmacoeconomic outcomes in cardiovascular diseases'. Together they form a unique fingerprint.Citation
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver